Let’s look at this from another angle. Aeon Biopharma—EOLS’ former parent company and the licensee of Daewoong’s botulinum toxin for therapeutic indications—issued its own PR on the Korean court ruling.
Aeon’s PR employs less definitive language than EOLS’ PR, so I’ve highlighted some of the waffle words in Aeon’s PR:
My question to you, Joe, is why would Aeon have to use waffle words such as, “expected” and “contemplates” if the settlement agreement with Medytox was an absolute guarantee of access to Daewoong’s toxin supply?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.